Objective: In this study, it was aimed to carry out computational studies for the development of new molecules for the inhibition of the cyclophilin D (CypD) receptor, which causes the disability of mitochondrial function in multiple sclerosis (MS) disease.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: In this study, it was aimed to carry out computational studies for the development of new molecules for the inhibition of the cyclophilin D (CypD) receptor, which causes the disability of mitochondrial function in multiple sclerosis (MS) disease.
📊
Key Findings & Data:Objective: In this study, it was aimed to carry out computational studies for the development of new molecules for the inhibition of the cyclophilin D (CypD) receptor, which causes the disability of mitochondrial function in multiple sclerosis (MS) disease.
💡
Conclusion & Impact:Objective: In this study, it was aimed to carry out computational studies for the development of new molecules for the inhibition of the cyclophilin D (CypD) receptor, which causes the disability of mitochondrial function in multiple sclerosis (MS) disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Farmakofor modelleme · in silico · moleküler doking
Abstract
Objective: In this study, it was aimed to carry out computational studies for the development of new molecules for the inhibition of the cyclophilin D (CypD) receptor, which causes the disability of mitochondrial function in multiple sclerosis (MS) disease.
Özet
Amaç: Bu çalışmada, multipl skleroz (MS) hastalığında mitokondriyal fonksiyon bozukluğuna neden olan siklofilin D (CypD) reseptörünün inhibisyonu için yeni moleküllerin geliştirilmesine yönelik hesaplamalı çalışmaların yapılması amaçlanmıştır.
YALCİN, G., HUYLU, B. (2022). DEVELOPMENT OF NEW CYCLOPHILIN D RECEPTOR INHIBITORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 46 - Sayı: 2, 458–473. https://ajindex.com/articles/401149
Alavian, K. N., Beutner, G., Lazrove, E., Sacchetti, S., Park, H. A., Licznerski, P., Li, H., Nabili, P., Hockensmith, K., Graham, M., Porter, G. A., Jonas, E. A. (2014). An uncoupling channel within the c-subunit ring of the F1F O ATP synthase is the mitochondrial permeability transition pore. Proceedings of the National Academy of Sciences of the United States of America, 111(29), 10580–10585. [CrossRef] Azzolin, L., Antolini, N., Calderan, A., Ruzza, P., Sciacovelli, M., Marin, O., Mammi, S., Bernardi, P., Rasola, A. (2011). Antamanide, a derivative of amanita phalloides, is a novel inhibitor of the mitochondrial permeability transition pore. PLoS ONE, 6(1), 26–29. [CrossRef] Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn II, G. W., Molkentin, J. R. (2004). Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature, 430(7003), 984–984. [CrossRef] Basso, E., Fante, L., Fowlkes, J., Petronilli, V., Forte, M. A., Bernardi, P. (2005). Properties of the permeability transition pore in mitochondria devoid of cyclophilin D. Journal of Biological Chemistry, 280(19), 18558–18561. [CrossRef] Basso, E., Petronilli, V., Forte, M. A., Bernardi, P. (2008). Phosphate is essential for inhibition of the mitochondrial permeability transition pore by cyclosporin A and by cyclophilin D ablation. Journal of Biological Chemistry, 283(39), 26307–26311. [CrossRef] Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235–242. [CrossRef] Clarke, S. J., McStay, G. P., Halestrap, A. P. (2002). Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. Journal of Biological Chemistry, 277(38), 34793–34799. [CrossRef] Daina, A., Michielin, O., Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(October 2016), 1–13. [CrossRef] Damsker, J. M., Bukrinsky, M. I., Constant, S. L. (2007). Preferential chemotaxis of activated human CD4 + T cells by extracellular cyclophilin A. Journal of Leukocyte Biology, 82(3), 613–618. [CrossRef] Dassault Systèmes. (2019). Discovery Studio Vi